

Cristiana Vitale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7713368/publications.pdf>

Version: 2024-02-01

30
papers

1,348
citations

623699

14
h-index

454934

30
g-index

32
all docs

32
docs citations

32
times ranked

2177
citing authors

#	ARTICLE	IF	CITATIONS
1	Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 149-156.	1.5	23
2	Needs of standardisation in reporting a venous lower limb ultrasound exam for the assessment of varicose veins. <i>Phlebology</i> , 2021, 36, 665-667.	1.2	1
3	Can we prevent "frailtyism"? <i>European Journal of Cardiovascular Nursing</i> , 2021, 20, 731-732.	0.9	1
4	Expert consensus on the conservative management of patients with chronic venous disease in CEAP clinical classes C0s-C3 in Italy. <i>Phlebology</i> , 2020, 35, 316-324.	1.2	3
5	Antidepressants and the Risk of Cardiovascular Events in Elderly Affected by Cardiovascular Disease. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 112-121.	1.4	11
6	Multidimensional Approach to Frailty. <i>Frontiers in Psychology</i> , 2020, 11, 564.	2.1	57
7	Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1299-1305.	7.1	144
8	Response letter to Dr. William's letter to the editor entitled "The CARVIVA HF trial - Is the devil in the detail?" published August 2018. <i>International Journal of Cardiology</i> , 2019, 288, 114.	1.7	0
9	Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861983813.	2.4	11
10	Frailty in patients with heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, L12-L16.	0.1	21
11	Assess frailty but avoid frailtyism. <i>European Heart Journal Supplements</i> , 2019, 21, L17-L19.	0.1	4
12	Care plans for the older heart failure patient. <i>European Heart Journal Supplements</i> , 2019, 21, L32-L35.	0.1	6
13	All-cause mortality and antipsychotic use among elderly persons with high baseline cardiovascular and cerebrovascular risk: a multi-center retrospective cohort study in Italy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 179-188.	3.3	8
14	Adherence to Antidepressants and Mortality in Elderly Patients with Cardiovascular Disease. <i>Clinical Drug Investigation</i> , 2018, 38, 593-602.	2.2	11
15	Frailty in Heart Failure: Implications for Management. <i>Cardiac Failure Review</i> , 2018, 4, 104.	3.0	64
16	Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure. <i>Cardiac Failure Review</i> , 2018, 4, 1.	3.0	9
17	Are elderly and women under-represented in cardiovascular clinical trials? Implication for treatment. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 433-438.	1.9	14
18	Effect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know?. <i>International Journal of Cardiology</i> , 2016, 224, 145-148.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, 55.	6.8	4
20	Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1. <i>European Heart Journal</i> , 2015, 36, 2677-2680.	2.2	131
21	Metabolic approach to heart failure: The role of metabolic modulators. <i>Egyptian Heart Journal</i> , 2015, 67, 177-181.	1.2	4
22	Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 331-339.	2.1	4
23	Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. <i>Hypertension</i> , 2015, 66, 1138-1144.	2.7	38
24	Revival of beta-blockers in arterial hypertension. <i>International Journal of Cardiology</i> , 2013, 163, 108.	1.7	2
25	Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina – The VASCO-angina study. <i>International Journal of Cardiology</i> , 2013, 168, 1078-1081.	1.7	50
26	Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: The NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. <i>International Journal of Cardiology</i> , 2012, 155, 279-284.	1.7	35
27	Trimetazidine improves exercise performance in patients with peripheral arterial disease. <i>Pharmacological Research</i> , 2011, 63, 278-283.	7.1	37
28	Gender differences in the cardiovascular effect of sex hormones. <i>Nature Reviews Cardiology</i> , 2009, 6, 532-542.	13.7	281
29	Metabolic Therapy for Patients with Diabetes Mellitus and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2006, 98, 14-18.	1.6	225
30	Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. <i>European Heart Journal</i> , 2004, 25, 1814-1821.	2.2	140